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Summary and conclusions
The respiratory distress syndrome (RDS) of the preterm infant , also called Hyaline
Membrane Disease (HMD), remains a significant cause of morbidity and mortality
despite improvements in neonatal care. RDS is caused by structural immaturity of the
lungs and by reduced amounts of pulmonary surfactant. Surfactant lowers the surface
tension at the air-liquid interface and is located inside all the alveoli ofthe lungs. In case
ofsurfactant deficiency, the lungs do not expand easily and once expanded they readily
collapse so that gas exchange becomes ineffective. The endotracheal administration of
surfactants to prevent or to reduce the severity of RDS is widely investigated in clinical
studies. Although most of the infants respond beneficially to a dose of surfactant, these
immediate effects are sometimes followed by a relapse several hours later. Moreover,
a large numberof the surviving premature infants develop a chronic lung disease called
bronchopulmonary dysplasia.
These lung abnormalities may be caused by an inhomogeneous distribution of the
administered surfactant. Atelectasis will remain in those lung segments that did not
receive surfactant, while overdistension will result in those lung segments reached by
surfactant. As a result of overdistension the bronchiolar and alveolar epithelial cells
become damaged and serum proteins that inactivate surfactant leak into the alveoli. This
process triggers a vicious circle and gradually the number of atelectatic terminal air
spaces increases. Moreover the epithelial injury initiates an inflammatory reaction
which may compromise healing so that finally bronchopulmonary dysplasia develops.
An inhomogeneous distribution of surfactant may therefore, at least in part, explain the
limited outcome of surfactant therapy. This whole process may be prevented if the
administration of surfactant could be improved in such a way that a homogeneous
distribution of surfactant in the lungs can be obtained (Chapter 1).
The distribution of surfactant after endotracheal administration was studied in a
rabbit model (Chapter 2). To induce surfactant deficiency in these rabbits the lungs
were flushed with physiological saline solution to wash out the surfactant. Surfactant
administered to premature infants with surfactant deficiency is suspended in a small
fluid volume to avoid interventions with gas exchange. We showed in our rabbit model,
however, that the endotracheal administration of such a small volume surfactant results
in an inhomogeneous distribution of surfactant. By increasing the volume in which the
surfactant was suspended, we could obtain a more homogeneous distribution of
surfactant. However, the endotracheal administration of a large volume fluid with
surfactant impairs gas exchange (Chapter 3). The large volume of fluid needs to be
absorbed by the lungs first before adequate gas exchange in the lungs can be estatrlished.
An attempt to improve gas exchange by increasing the ventilator inspiratory pressures
failed and contributed to the death of all rabbits during the experinrent. Gas exchange
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could effectively be supported by using an artificial lung. In this situation blood is
pumped extracorporeally through an artificial lung in which gas exchange takes place.
This system is called extracorporeal life support (ECLS) and is comparable to an
artificial placenta.
The idea of using ECLS to support premature infants has already been explored in
the 1960s. Unfortunately, the inherent side effects of extracorporeal circulation, in
particular bleeding, excluded successful outcome in these premature infants already at
risk for intracranial bleeding. In term infants with less risk for intracranial bleeding
ECLS for severe respiratory failure is successfully applied.
To evaiuate the cunent risk for bleeding during neonatal ECLS we studied
retrospectively our latest clinical results (Chapter 4). This study indicated that it is
necessary to transfuse continuously platelets during neonatal ECLS to maintain adequate
platelet numbers to prevent bleeding. The continuous platelet consumption might
primarily be related to the large priming volume of the ECLS circuit, which requires to
start with a large population of donor platelets. The short life span and poor functioning
of donor platelets necessitates to supply continuously platelets. Miniaturization of the
circuit may decrease the need for donor platelets and this may be essential to improve
hemostasis during neonatal ECLS.
Besides miniaturization of the circuit it is also necessary to reduce the activation
of blood with the materials of the ECLS circuit. The main factors involved in this
reaction are the contact and complement systems. Contact activation results in an
impaired platelet function causing bleeding tendency, while complement activation
results in leukocyte activation causing organ dysfunction.
We showed that two periods of blood activation could be distinguished during
neonatal ECLS (Chapter 5). The first activation pattem started immediately after the
start of ECLS and subsided by 24 hours. A second activation was observed 72 hours after
start of ECLS that lasted until the end of ECLS. The initial blood-material interaction
resulted in an immediate activation of both the contact and the complement system. This
activation pattem may account for the consumption of platelets and the increased risk
for bleeding but also for leukocyte activation and the temporary further compromised
lung function frequently observed in these infants.The second activation was characterized
by only increased clotting and fibrinolytic activity, while no activationofthecomplement
system was observed. This may be caused by inappropriate anticoagulation obtained
with heparin.
In experimental studies in rabbits we showed that by taking additional measures the
effects of blood-material interactions can be modified (Chapter 6). If during
extraco{poreal circulation through a simplified and small prime circuit blood activation
was modified by the administration of a specific drug (tranexamic acid) initial platelet
consumption could be prevented. In addition, these studies also showed that heparin
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Chapter 8
coating adequately prevented activation of the clotting system. This suggests that it is
possible to perform extracorporeal circulation with minimal or no systemically
administered heparin, thus avoiding the risk of bleeding by anticoagulation.
Furthermore we demonstrated that heparin coated circuits not only prevented the
activation ofclotting systembut it also reduced complement activation and consequently
the release of leukocyte inflammatory mediators (Chapter 7). We can therefore expect
that the use of heparin coated circuits during ECLS may also prevent the initial
compromised lung function caused by inflammatory mediators.
We anticipate that by miniaturization of the circuit and by taking the forementioned
measures to reduce blood activation, ECLS can also be safely applied in preterm infants
with severe respiratory failure. This makes it feasible to administer a large volume fluid
with surfactant by which an optimal distribution of surfactant can be obtained. With
these new possibilities successful improvement may be achieved over the culrent
treatment of premature infants with severe respiratory failure.
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